Biotech Values

[DewDiligence]

Re: SNMX

Thanks, Ant. That was quite an interesting post.

After doing some cursory DD on SNMX I am turned off but what I’ve encountered. First, there was the releasing of news to coincide with the December IPO lockup expiration (#msg-4977145). Further, at the recent First Albany presentation, the CEO grossly hyped the size of the potential market on which SNMX’s royalties will be based.

The FEMA/GRAS process remains one of the oddities of the FDA’s jurisdiction, and perhaps SNMX will profit handsomely from it some day. But I’ve already seen enough to stay away, at least for now.